In today’s rapidly evolving environment, drug and device companies face new challenges to deliver better patient outcomes at lower costs. KPMG is a leading advisor to the Life Sciences industry, providing a wide range of services to help organizations grow their business, enhance performance, and manage risks.
We offer a market-leading portfolio of methodologies, tools and services to assist Life Science companies in the following areas:
Independent audit and assurance services
Analyses and assessments on R&D effectiveness
Transactions (due diligence, integration and separation)
Tax compliance and governance
Value chain analysis
Risk management and regulatory compliance
Disruptive technologies and advanced analytics
Contact
KPMG Basel
Viaduktstrasse 42
PO Box 3456
4002 Basel
Tel. +41 58 249 91 91
Fax +41 58 249 91 23
KPMG Life Sciences Team Switzerland: https://home.kpmg.com/ch/en/home/industries/life-sciences.html
Patient-driven drug pricing, the uncertain future of Switzerland’s tax regime, and new business models for life science innovators in a changing global market are just a few of the topics…
Ahead of the 78th session of the United Nations General Assembly (UNGA78), IFPMA Director General Thomas Cueni underscores the need for pandemic preparedness plans to support innovation and equity. Global…
Regular contributor Brendan Shaw* casts his eye over the recently announced 2023 WHO Essential Medicines List, how it reflects growing pharmaceutical innovation, and why maintaining a ‘seat at the table’…
Following the appointment of new boards at the US innovative pharma industry body PhRMA, and its European counterpart EFPIA, it is global group the IFPMA’s turn to reveal a new…
At this year’s Swiss Biotech Day, the Swiss Biotech Association celebrated its 25 years of existence and proved the ability of the sector to weather geopolitical disruptions and funding challenges…
Brendan Shaw examines the protracted efforts of global stakeholders to come together around a global pandemic treaty and outlines the benefits of constructive engagement on the part of the pharmaceutical…
Global biopharma is increasingly moving towards biologic medicines, which promise a greater impact on patient’s lives than the small-molecule drugs that preceded them, but which come with significant added costs…
Writing in the June 2023 edition of DIA’s Global Forum magazine, Angelika Joos of MSD and Susanne Ausborn Roche consider some of the key takeaways from a workshop on regulatory…
Takeda’s Mwana Lugogo and Pfizer’s Rady Johnson, the current and former chairs of the IFPMA Ethics & Business Integrity Committee and Chief Ethics & Compliance Officers Roundtable respectively, highlight the…
The Contract Development and Manufacturing Organization (CDMO) sector has flousished in recent years as Big Pharma has shifted its attention to its core R&D activities and outsourced other supply chain…
IFPMA Director General Thomas Cueni highlights the global innovative pharmaceutical industry’s five key priorities for ensuring better national and international healthcare responses to future pandemics, drawing on the lessons of…
The Medicines Patent Pool (MPP) is a United Nations-backed public health organisation working to increase access to, and facilitate the development of, life-saving medicines for low- and middle-income countries. Executive…
In spite of the spectacular healthcare advances the world has seen in recent decades and increasing evidence that gender equality is not only an ethical necessity, but a decisive component…
See our Cookie Privacy Policy Here
